A Change of Heart: the New Era of Heart Failure Management

[1] Mozzafarian D(2016)On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association Circulation 133 e38-e360

[2] Benjamin EJ(2014)Angiotensin–neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 993-1004

[3] Go AS(2008)Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double blind, placebo-controlled trial Lancet 372 807-816

[4] Arnett DK(2010)Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 376 875-885

[5] Blaha MJ(2013)2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines J Am Coll Cardiol 62 e147-e239

[6] Cushman M(2013)Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) Eur J Heart Fail 15 1062-1073

[7] McMurray JJV(2004)Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial Am J Hypertens 17 103-111

[8] Packer M(2015)Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure Circulation 131 54-61

[9] Desai AS(2016)Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomised comparison of two up-titration regimens Eur J Heart Fail 13 18-28

[10] Gong J(2011)Epidemiology and clinical course of heart failure with preserved ejection fraction Eur J Heart Fail 16 260-267

[1] Mozzafarian D(2016)On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association Circulation 133 e38-e360

[2] Benjamin EJ(2014)Angiotensin–neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 993-1004

[3] Go AS(2008)Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double blind, placebo-controlled trial Lancet 372 807-816

[4] Arnett DK(2010)Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 376 875-885

[5] Blaha MJ(2013)2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines J Am Coll Cardiol 62 e147-e239

[6] Cushman M(2013)Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) Eur J Heart Fail 15 1062-1073

[7] McMurray JJV(2004)Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial Am J Hypertens 17 103-111

[8] Packer M(2015)Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure Circulation 131 54-61

[9] Desai AS(2016)Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomised comparison of two up-titration regimens Eur J Heart Fail 13 18-28

[10] Gong J(2011)Epidemiology and clinical course of heart failure with preserved ejection fraction Eur J Heart Fail 16 260-267